Article
Immunology
Asia -Sophia Wolf, Elena Mitsi, Scott Jones, Simon P. Jochems, Lucy Roalfe, Deus Thindwa, James E. Meiring, Jacquline Msefula, Farouck Bonomali, Tikhala Makhaza Jere, Maurice Mbewe, Andrea M. Collins, Stephen B. Gordon, Melita A. Gordon, Daniela M. Ferreira, Neil French, David Goldblatt, Robert S. Heyderman, Todd D. Swarthout
Summary: This study investigates the protective mechanism of childhood pneumococcal conjugate vaccine (PCV) against pneumococcal carriage. The results show no clear relationship between antibody quality and protection from carriage, suggesting that PCV13-driven antibody quality may mature with age and exposure.
Article
Immunology
Kathryn J. Britton, Janessa L. Pickering, William S. Pomat, Camilla de Gier, Monica L. Nation, Casey L. Pell, Caitlyn M. Granland, Vela Solomon, Rebecca L. Ford, Andrew Greenhill, Jason Hinds, Hannah C. Moore, Peter C. Richmond, Christopher C. Blyth, Deborah Lehmann, Catherine Satzke, Lea-Ann S. Kirkham
Summary: The study found that in Papua New Guinea, PCV13 had no impact on pneumococcal carriage density, even for vaccine serotypes. The low prevalence of vaccine serotypes, high pneumococcal carriage density, and abundance of non-vaccine serotypes likely contribute to the lack of PCV13 impact on carriage in Papua New Guinean infants.
Article
Pediatrics
Satoshi Kamidani, Lakshmi Panagiotakopoulos, Charles Licata, Matthew F. Daley, W. Katherine Yih, Ousseny Zerbo, Hung Fu Tseng, Malini B. DeSilva, Jennifer C. Nelson, Holly C. Groom, Joshua T. B. Williams, Simon J. Hambidge, James G. Donahue, Ermias D. Belay, Eric S. Weintraub
Summary: This study investigated the risk of Kawasaki disease (KD) following 13-valent pneumococcal conjugate (PCV13) and rotavirus vaccines in children under 2 years of age. The results showed that there was no increased risk of KD following PCV13 and rotavirus vaccination in this age group.
Article
Infectious Diseases
Jiachen Wang, Yujue Wang, Ruoyu Xu, Ting Zhang, Yanyan Jiang, Yuanyuan Wang, Yi Wang, Yuanze Du, Wenxue Sun, Kai Deng, Weizhong Yang, Zengwu Wang, Luzhao Feng, Chunping Wang
Summary: Weifang City implemented an innovative strategy for PCV13 vaccination, providing free vaccines and reducing prices to increase vaccination coverage. However, the coverage is still lower than that in developed countries. To further promote PCV13 vaccination, Weifang City should continue to implement this strategy and explore appropriate financing channels.
INFECTIOUS DISEASES OF POVERTY
(2023)
Article
Immunology
Yan Li, Huaqing Wang, Wesley Furnback, Bruce C. M. Wang, Shuiqing Zhu, Peng Dong
Summary: The study found that vaccinating infants with PCV13 in cities like Beijing, Shanghai, Shenzhen, Chengdu, Karamay, Qingdao, and Suzhou is a cost-effective strategy, especially when considering both direct and indirect effects. Vaccination has significant benefits for infant health and improves quality of life while remaining cost-effective.
Article
Immunology
Kristiana Alexandrova Nikolova, Mikael Andersson, Hans-Christian Slotved, Anders Koch
Summary: The introduction of PCV13 in Greenland's childhood vaccination program in 2010 led to a decrease in overall incidence rates of IPD, with a significant decrease in children but a notable increase among the elderly. The incidence of vaccine serotype IPD decreased across all ages, while non-vaccine serotype IPD increased during the post-PCV13 period, particularly among the elderly aged 60 years and above. Continued surveillance of IPD in the Greenlandic population is needed to monitor the trend.
Article
Health Care Sciences & Services
Xiaozhen Lai, Cristina Garcia, Dan Wu, Maria Deloria Knoll, Haijun Zhang, Tingting Xu, Rize Jing, Zundong Yin, Brian Wahl, Hai Fang
Summary: This study aimed to evaluate the cost-effectiveness of including PCV13 in China's National Immunization Programme. The results showed that introducing PCV13 at the national level could significantly reduce pneumococcal cases and deaths, and it was cost-effective or cost-saving in 17 out of 31 provinces. Therefore, the importance of introducing PCV13 in China's National Immunization Programme is emphasized.
LANCET REGIONAL HEALTH-WESTERN PACIFIC
(2023)
Article
Microbiology
Erika Kurihara, Kenichi Takeshita, Saori Tanaka, Noriko Takeuchi, Misako Ohkusu, Haruka Hishiki, Naruhiko Ishiwada
Summary: We conducted a study of 34 cases of pediatric pneumococcal meningitis reported after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in Japan. Our results revealed that non-PCV13 serotypes were the main cause of pneumococcal meningitis in children, and all cases with sequelae and death were caused by non-PCV13 serotypes. Furthermore, all penicillin-resistant Streptococcus pneumoniae strains (26.5%; 9/34) belonged to non-PCV13 serotypes. We also analyzed the antimicrobial susceptibilities of isolated S. pneumoniae strains to glycopeptides, linezolid, and daptomycin. All tested strains were susceptible to vancomycin, teicoplanin, linezolid, and daptomycin, with daptomycin showing the best outcome. Pneumococcal meningitis in children remains an ongoing challenge, and monitoring the serotype and antimicrobial susceptibility of strains is crucial for informing treatment strategies.
MICROBIOLOGY SPECTRUM
(2022)
Article
Immunology
Ron Dagan, Bart Adriaan van der Beek, Shalom Ben-Shimol, Tamara Pilishvili, Noga Givon-Lavi
Summary: The study demonstrates that the 7-valent and 13-valent pneumococcal vaccines are effective in protecting against otitis media caused by specific serotypes, especially serotypes 19F and 19A.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Lassane Kabore, Tolulope Adebanjo, Berthe Marie Njanpop-Lafourcade, Soumeya Ouangraoua, Felix T. Tarbangdo, Bertrand Meda, Srinivasan Velusamy, Brice Bicaba, Flavien Ake, Lesley McGee, Seydou Yaro, Edouard Betsem, Alain Gervaix, Bradford D. Gessner, Cynthia G. Whitney, Jennifer C. Moisi, Chris A. Van Beneden
Summary: Within 3 years of PCV13 implementation in Burkina Faso, substantial reductions in the percentage of pneumococcal carriers with a vaccine-type were documented among children under 5 years old, but not among individuals aged 5 years and above. More time, a change in the PCV13 schedule, or both, may be needed to better control pneumococcal carriage in this setting.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Immunology
Ravinder Kaur, Minh Pham, Karl O. A. Yu, Michael E. Pichichero
Summary: The study found that antibiotic susceptibility of Streptococcus pneumoniae strains isolated from children improved initially after the introduction of PCV13, but began to decrease from 2013 onwards due to the emergence of new serotypes not included in PCV13. These new strains exhibit reduced susceptibility to multiple commonly used antibiotics, compared to the pre-PCV13 era.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Leah J. Ricketson, Julie A. Bettinger, Manish Sadarangani, Scott A. Halperin, James D. Kellner
Summary: An indirect cohort analysis was conducted to examine the vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in children in Canada. The study found that PCV7 had an effectiveness of 96% and PCV13 had an effectiveness of 55% against vaccine serotypes. PCV13 had lower effectiveness against serotypes 3 and 19A but still provided good protection against other serotypes.
Article
Immunology
Juliette Romaru, Mathilde Bahuaud, Gauthier Lejeune, Maxime Hentzien, Jean-Luc Berger, Ailsa Robbins, Delphine Lebrun, Yohan N'Guyen, Firouze Bani-Sadr, Frederic Batteux, Amelie Servettaz
Summary: This study evaluated the immunological response and protection in HIV patients with a CD4 cell count above 200 cells/μL after receiving a single dose of PCV13. The results showed that PCV13 induced immune response and protection in these patients at one month, and over half of the patients remained immunologically protected at one year after vaccination.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Kaile Chen, Xiyan Zhang, Yunzhen Tao, Yunzhong Wang, Jian Xue, Changpeng Liu, Shuang Feng, Yongdong Yan, Qinghui Chen, Jianmei Tian, Genming Zhao, Xuejun Shao, Tao Zhang
Summary: This study described the hospitalization of 105 children <5 years of age for IPD in a hospital in Suzhou, China, from 2010 to 2017, and calculated the incidence rate of IPD in Suzhou. Eight different capsular serotypes of pneumococcus were identified in the study.
EMERGING INFECTIOUS DISEASES
(2021)
Article
Microbiology
Yuliang Zhao, Guohua Li, Shengli Xia, Qiang Ye, Lin Yuan, Hong Li, Jiangjiao Li, Jingjing Chen, Shuyuan Yang, Zhiwei Jiang, Guoqing Zhao, Rongcheng Li, Yanping Li, Jielai Xia, Zhen Huang
Summary: The study aimed to determine the non-inferiority of the seven common serotypes in PCV13 compared to PCV7, and the superiority of its six additional serotypes. The results showed that PCV13 was immunogenic for all serotypes and had a comparable safety profile to PCV7.
FRONTIERS IN MICROBIOLOGY
(2022)